Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Cancer: Breakthrough Pain × Ketamine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 13 Pain 12 Pain, Postoperative 10 Depression 8 Agnosia 8 Breast Neoplasms 7 Anxiety Disorders 6 Head and Neck Neoplasms 5 Chronic Pain 5 Acute Pain 4 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Pancreatic Neoplasms 3 Pain, Intractable 3 Lymphoma, Follicular 3 Colorectal Neoplasms 3 Prostatic Neoplasms 2 Gastrointestinal Neoplasms 2 Colonic Neoplasms 2 Cancer Pain 2 Waldenstrom Macroglobulinemia 1 Thrombocythemia, Essential 1 Stomatitis 1 Sezary Syndrome 1 Rectal Neoplasms 1 Primary Myelofibrosis 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Postoperative Analgesia 1 Polycythemia Vera 1 Peripheral Nervous System Diseases 1 Pelvic Neoplasms 1

Interventions

Morphine 1 Ketamine 1 Chitosan 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02591017 2018-11-13

ONKEMI

University Hospital, Basel, Switzerland

Phase 3 Terminated

Cancer: Breakthrough Pain

Data powered by HemOnc (CC BY 4.0) Colophon ⚡